161 related articles for article (PubMed ID: 24285338)
1. HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.
Choe EY; Wang HJ; Kwon O; Cho Y; Huh KH; Kim MS; Kim YS; Ahn CW; Cha BS; Lee HC; Kang ES
Transplantation; 2014 Feb; 97(4):419-25. PubMed ID: 24285338
[TBL] [Abstract][Full Text] [Related]
2. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
3. Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels.
Cho Y; Lee MJ; Choe EY; Jung CH; Joo DJ; Kim MS; Cha BS; Park JY; Kang ES
Liver Transpl; 2014 May; 20(5):557-63. PubMed ID: 24477986
[TBL] [Abstract][Full Text] [Related]
4. Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Cho Y; Choe E; Lee YH; Seo JW; Choi Y; Yun Y; Wang HJ; Ahn CW; Cha BS; Lee HC; Kang ES
Metabolism; 2015 Apr; 64(4):482-8. PubMed ID: 25312577
[TBL] [Abstract][Full Text] [Related]
5. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
7. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
Navarro-Muñoz M; Bonet J; Bayés B; Lauzurica R; Blanco S; Romero R
Transplant Proc; 2007 Sep; 39(7):2259-63. PubMed ID: 17889157
[TBL] [Abstract][Full Text] [Related]
9. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
11. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
Fellström B; Abedini S; Holdaas H; Jardine AG; Staffler B; Gimpelewicz C;
Clin Transplant; 2006; 20(6):732-9. PubMed ID: 17100723
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
Crespo-Leiro MG; Paniagua MJ; Marzoa R; Grille Z; Naya C; Flores X; Rodriguez JA; Mosquera V; Franco R; Castro-Beiras A
Transplant Proc; 2008 Nov; 40(9):3060-2. PubMed ID: 19010194
[TBL] [Abstract][Full Text] [Related]
13. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
14. Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase.
Sadoni S; Kaczmarek I; Delgado O; Schmöckel M; Reichart B; Meiser B
Transplant Proc; 2007 Mar; 39(2):558-9. PubMed ID: 17362781
[TBL] [Abstract][Full Text] [Related]
15. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
16. The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
Lam HC; Chu CH; Wei MC; Keng HM; Lu CC; Sun CC; Lee JK; Chuang MJ; Wang MC; Tai MH
Exp Biol Med (Maywood); 2006 Jun; 231(6):1010-5. PubMed ID: 16741040
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced liver injury associated with statins.
Russo MW; Scobey M; Bonkovsky HL
Semin Liver Dis; 2009 Nov; 29(4):412-22. PubMed ID: 19826975
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes.
Colivicchi F; Tubaro M; Santini M
Int J Cardiol; 2011 Oct; 152(1):56-60. PubMed ID: 20674999
[TBL] [Abstract][Full Text] [Related]
20. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
